Pharmacist’s Role in Modern Menopause Care Beyond Black Box Warnings

For decades, the pharmacy counter has been a site of hesitation for women seeking relief from menopausal symptoms, often due to the stark safety warnings that once dominated the packaging of hormone replacement therapy (HRT). This landscape changed fundamentally when the FDA officially approved significant labeling updates for 6 menopausal hormone therapy products, removing risk statements regarding cardiovascular disease, breast cancer, and probable dementia from the black box warning.^1,2

This regulatory shift marks the end of an era defined by what health officials describe as a distortion of risk rooted in early 2000s research, and it signals a new, evergreen responsibility for pharmacists to provide evidence-based guidance to a population that will spend a third of their lives in the menopausal transition.²

“Menopause is having a moment,” Kathleen Vest, PharmD, professor or pharmacy practice at Midwestern University, and Brooke Griffin, PharmD, professor of pharmacy practice and vice chair of clinical services at Midwestern University, told Drug Topics. “This is a good thing because patients are seeing more and more information in the media—both through newscasts and social media—about this transition. While not every patient is initiating this conversation, the ones that do are really looking to make an informed decision about their options.”

Vest and Griffin added that with the removal of the black box warnings, patients will have access to products that can help with vaginal dryness and urinary symptoms, thus improving a patient’s quality of life.

A Look Back at Menopause Care

To understand why this change is so pivotal for modern pharmacy practice, one must look back at the 2002 Women’s Health Initiative (WHI) study, which originally prompted the restrictive warnings. That study involved participants with an average age of 63 years—more than a decade past the typical onset of menopause—and utilized hormone formulations that are no longer the primary standard of care.^2,3

For 20 years, these findings created a medical dogma that caused HRT use to plummet, leaving tens of millions of women to suffer through life-altering symptoms without treatment. The FDA’s recent comprehensive review acknowledges that when hormone therapy is initiated near the onset of menopause, the benefit-to-risk ratio is significantly more favorable than previously suggested.^2,3

“Since its publication, there have been many patients for whom HRT was not offered due to concerns of risks. It is important to understand the warnings and educate patients that for urinary symptoms and vaginal dryness, products are available to help these symptoms while minimizing cardiovascular risks,” Vest and Griffin said. “The Menopause Society offers guidance that the benefits outweigh the potential risks of hormone therapy for patients who are less than 60 years of age, within 10 years of menopause, and have no contraindications to hormone therapy.”

They added that not every patient will need HRT, and some might only need localized or topical medications, adding that the benefits and risks should be evaluated yearly.

The Pharmacist’s Role in Women’s Health

Effective care now requires a deep understanding of individualization, as the safety of HRT is highly dependent on the choice of agent and route of administration. Pharmacists should be prepared to discuss why transdermal patches, gels, and sprays may be a safer choice for patients with moderate cardiovascular risk, as these formulations often confer a lower risk of venous thromboembolism and stroke compared with oral tablets.¹

“Patients are concerned about hot flashes, sleep disturbances, and brain fog—which are very real and can interfere with a patient's quality of life. The loss of bone mass, however, isn't something patients can ‘feel’ happening, so that is one area where pharmacists can really educate patients on this silent effect,” Vest and Griffin said. “While bone loss may be inevitable, fracture risk can be mitigated with some lifestyle changes and potential supplements/medications.”

Although the FDA removed several boxed warnings, the agency has intentionally retained the warning for endometrial cancer for systemic estrogen-alone products, emphasizing that the pharmacist's role in monitoring for established adverse effects remains constant. For patients where hormones are strictly contraindicated—such as those with a history of breast cancer or active liver disease—pharmacists provide essential counseling on nonhormonal alternatives like selective serotonin reuptake inhibitors or newly approved nonhormonal medications specifically for vasomotor symptoms.^1-3

The pharmacist’s expertise is also crucial in steering patients toward FDA-approved products and away from compounded bioidentical hormones, which lack federal regulation and may vary dangerously in strength and purity.

“Most pharmacists learn about menopause in pharmacy school, and it may be 1 to 2 hours of lecture content. Pharmacists should stay up to date with this topic post-graduation because they are going to be fielding a lot of questions in their careers,” Vest and Griffin said. “Patients spend almost a third of their lives in the peri- and post-menopausal transition, and our aging population will need our support and knowledge of their options.”

They added that many pharmacists were trained to avoid HRT in patients experiencing menopause, so staying up to date with recommendations and literate is important to provide the best care to patients. Further, pharmacists can talk with patients about symptoms so that they can best identify treatment for them.

By embracing this evolving role, pharmacists can empower women to make informed choices that not only alleviate immediate symptoms but also protect their long-term health and vigor.

“Pharmacists can become Certified Menopause Providers through the Menopause Society, and I foresee many pharmacists earning this credential to help the patients in their practice,” Vest and Griffin said. “The best first step a pharmacist can take, regardless of expertise, is to remember that you don't have to be an expert to help someone and take every opportunity you can to learn more about this!”

READ MORE: Women’s Health Resource Center

Are you ready to elevate your pharmacy practice? Sign up today for our free Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips straight to your inbox.

REFERENCES

1. Gallagher A. FDA removes black box warning on 6 menopausal hormone therapy products. Drug Topics. February 12, 2026. Accessed May 29, 2026. https://www.drugtopics.com/view/fda-removes-black-box-warning-on-6-menopausal-hormone-therapy-products

2. HHS advances women’s health, removes misleading FDA warnings on hormone replacement therapy. News release. FDA. November 10, 2025. Accessed May 29, 2026. https://www.fda.gov/news-events/press-announcements/hhs-advances-womens-health-removes-misleading-fda-warnings-hormone-replacement-therapy

3. Fact sheet: FDA initiates removal of “black box” warnings from menopausal hormone replacement therapy products. News release. HHS. November 10, 2025. Accessed May 29, 2026. https://www.hhs.gov/press-room/fact-sheet-fda-initiates-removal-of-black-box-warnings-from-menopausal-hormone-replacement-therapy-products.html